Shilpa Medicare Q1 FY27 Results & Earnings Intelligence
SHILPAMEDStructural risk assessment following Q1-FY27 | 30 Jun 26 earnings.
₹468.9 Cr
+43.0% YoY•+6.9% QoQ
₹92.1 Cr
+83.0% YoY•-23.5% QoQ
₹100.9 Cr
+115.2% YoY•-6.4% QoQ
20/ 100
−5 pts QoQ
The Quarter at a Glance
Consolidated Financials| Metric | Q1-FY27 | 30 Jun 26 | Q1-FY26 | 30 Jun 25 | YoY Δ | Q4-FY26 | 31 Mar 26 | QoQ Δ |
|---|---|---|---|---|---|
| Total Revenue / Income | ₹468.9 Cr | ₹327.8 Cr | +43.0% | ₹438.7 Cr | +6.9% |
| Profit Before Tax (PBT) | ₹92.1 Cr | ₹50.3 Cr | +83.0% | ₹120.5 Cr | -23.5% |
| Net Profit (PAT) | ₹100.9 Cr | ₹46.9 Cr | +115.2% | ₹107.8 Cr | -6.4% |
Sources:Official BSE/NSE Disclosures & Financial Filings
Sentinel Executive Summary
Core Earnings Synthesis"Shilpa Medicare Limited currently sits within Flagium's Watch category. However, recent periods have remained stable with minor operational friction. Steady top-line performance and clean accounting records help keep structural risk contained. Current deterioration appears cyclical rather than existential."
Shilpa Medicare Limited posted steady top-line growth and bottom-line stability, demonstrating resilient execution in its core markets. While the underlying business remains fundamentally sound, the presence of 0 active risk warnings highlights minor operational or working capital inefficiencies to keep on the watch list.
🟢 Key Operational & Structural Positives
- ✓Revenue Growth: Quarterly revenue moved +43.0% YoY and +6.9% QoQ, reflecting demand and volume trends.
- ✓Net Profit Expansion: Profit after tax moved +115.2% YoY and -6.4% QoQ, settling at ₹100.9 Cr.
- ✓Operating Margins: Operating margin moved +429 bps YoY and +206 bps QoQ to 19.64%.
⚠️ Key Areas of Watch & Margin Pressures
- ⚠Raw material price movement and its impact on operating margins.
- ⚠Working capital efficiency and cash flow conversions.
- ⚠Domestic demand recovery and segment-wise volume growth.
Total Revenue / Income expanded across both horizons (+43.0% YoY and +6.9% QoQ vs Q4-FY26), demonstrating synchronized top-line execution.
Flagium Risk Signals
Automated Forensic SignalsStabilization in key metrics
Financial reports demonstrate robust disclosure levels with no forensic or accrual warnings.
Leadership team stability remains intact with no auditor qualifications or key departures.
🎙️ Shilpa Medicare (SHILPAMED) Q1 FY27 Concall Intelligence
Management Commentary, Concall Takeaways & Key Discussion Themes
Management Tone
Bullish
Management focused on the company's transformation, operational leverage, and robust growth prospects, with confident and detailed commentary across divisions and forthcoming answers on strategy and outlook.
Key Themes & Management Discussion — SHILPAMED Concall Takeaways
Transformation & Operational Leverage
Management emphasized the shift from a debt-heavy API business to a diversified, innovation-driven company, highlighting that reinvestment is largely behind and harvesting is ahead, with operational leverage set to drive incremental revenue and margins.
“The reinvesting is largely behind us. The harvesting is ahead of us.”
CDMO & Pipeline Monetization
CDMO remains a core growth driver, with over 25 NCE programs in various stages and only one commercial product currently; management expects significant ramp-up as more programs mature, supported by selective investments and unique partnership strategies.
“We have more than 25 such NCE programs in various stages of development. I think as and when these molecules advance, you will see the growth.”
Biologics Division Expansion
Biologics is positioned for higher growth due to a small base and industry trends, with multiple biosimilars and NBE programs advancing, and a mixed strategy of CDMO, biosimilars, and strategic partnerships for long-term value creation.
“Our first European partnering of Nivolumab with Orion Corporation gives us further assurance on commercialization of our biosimilar pipeline globally.”
Formulation Division & Complex Products
The Formulation division is seeing robust growth, driven by complex FDA portfolio launches and strong order visibility, with global expansion plans for Nor-UDCA and other specialty products.
“Overall, given existing and new pipeline launches, there is a strong likelihood of robust growth possibility in Formulation.”
Capital Allocation & Capex Strategy
Management stated that significant capex in Biologics and Albumin is already done, with no major new investments needed for the next three years, focusing instead on sweating existing assets and selective capex in API and new Formulation molecules.
“We still feel that for at least the next 3 years, we don't need any significant capex in new investments such as Biologics or Albumin, where we have already invested a lot.”
Risks Mentioned by Management on Call
Risks Acknowledged in SHILPAMED Concall
- •Regulatory pathway challenges“Whilst we are working towards being very robust and compliant with our practices, once in a while, the way regulatory authorities look at us could be a bit different. And if some of those unexpected challenges come up, that might slow down the growth trajectory that we have.”
- •Global political situation impacting raw material prices“That also has to do with the recent political situation globally -- raw material prices have gone up, which ends up impacting margins, at least for the time being.”
- •U.S. tariff threats on pharmaceutical exports“I think the entire industry in India is still monitoring how the Trump administration will behave on that, and what the terms and conditions will be. I think once we have more clarity on that, it will be the right time to move on the next steps.”
What to do next
Explore SHILPAMED's full structural risk profile — 12Q score trajectory, pillar breakdown, flag history, and peer benchmarking.
View SHILPAMED profile →See how Healthcare peers and the broader market are positioned. Identify sector-wide stress or rotation signals.
Open market monitor →Check how this Q1-FY27 | 30 Jun 26 result affects your portfolio's overall risk exposure and concentration.
Review your portfolio →Continue Research
📬 Flagium Risk Brief — Track forensic risks on SHILPAMED & 3 market anomalies weekly
See a sample issue →Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics platform. Analysis reports are compiled programmatically from public regulatory XBRL submissions (NSE/BSE) for educational and research purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. This evaluation does not constitute investment advice, financial planning, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.